Incyte | INCY - Net Income



Incyte reported $405M in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Amgen USD 1.43B 298M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Exelixis USD 230.42M 70.8M Jul/2025
Gilead Sciences USD 1.96B 645M Jun/2025
Incyte USD 405M 246.8M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
MacroGenics USD -36250000 20.83M Jun/2025
Merck USD 4.43B 652M Jun/2025
Moderna USD -825000000 146M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.02B 418M Jun/2025
Novartis USD 4.04B 1.22B Jun/2025
Pfizer USD 2.91B 58M Jun/2025
PTC Therapeutics USD -64849000 931.41M Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025